07 April 2026 | News
Image Courtesy: Public Domain
Nightfood Holdings, Inc., (OTCQB: NGTF) doing business as TechForce Robotics, Inc., (“TechForce” or the “Company”), announced the execution of a Joint Development, Manufacturing, and Licensing Agreement with Oncotelic Therapeutics, Inc., (OTCQB: OTLC), a biotechnology and artificial intelligence-driven pharmaceutical platform company.
This strategic collaboration brings together TechForce Robotics’ advanced robotics engineering capabilities with Oncotelic’s proprietary AI-Enhanced technologies to jointly develop and commercialize AI-Enhanced, GMP-compliant robotic systems designed for pharmaceutical manufacturing and laboratory automation environments.
Unlocking New Opportunities in Biopharma Automation
The agreement represents an initial step in TechForce Robotics’ expansion into high-value, regulated industries, including biopharmaceutical manufacturing. By combining complementary expertise in robotics, automation, and AI-Enhanced pharmaceutical processes, the companies intend to develop integrated solutions aimed at improving operational efficiency, regulatory compliance, and scalability in pharmaceutical production environments.
“This partnership reflects our continued focus on deploying intelligent automation into complex, highly regulated industries,” said Jimmy Chan, CEO of TechForce Robotics. “We are pleased to collaborate with Oncotelic and believe their experience in biotechnology and AI-Enhanced platforms provides a foundation for this joint development effort.”
Highlighting Leadership Experience
Dr. Vuong Trieu, Chief Executive Officer of Oncotelic, brings decades of experience in oncology, drug development, and artificial intelligence applications in pharmaceutical innovation. Dr. Trieu has been involved in advancing multiple therapeutic and technology platforms and has contributed to the development and commercialization of novel healthcare solutions.
TechForce Robotics believes that the leadership and domain expertise of Dr. Trieu and his team enhance the strategic alignment of this collaboration, and support its long-term development objectives.
